You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMicafungin
Accession NumberDB01141  (APRD01114)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionMicafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
Structure
Thumb
Synonyms
Mycamine
External Identifiers
  • FK-463
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MycaminePowder, for solution50 mgIntravenousAstellas Pharma Canada Inc2007-09-18Not applicableCanada
MycaminePowder, for solution100 mgIntravenousAstellas Pharma Canada Inc2009-12-17Not applicableCanada
MycamineInjection, powder, lyophilized, for solution20 mg/mLIntravenousAstellas Pharma US, Inc.2006-06-27Not applicableUs
MycamineInjection, powder, lyophilized, for solution10 mg/mLIntravenousAstellas Pharma US, Inc.2005-03-16Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Micafungin sodium
ThumbNot applicableDBSALT001165
Categories
UNIIR10H71BSWG
CAS number235114-32-6
WeightAverage: 1270.274
Monoisotopic: 1269.438350313
Chemical FormulaC56H71N9O23S
InChI KeyPIEUQSKUWLMALL-YABMTYFHSA-N
InChI
InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1
IUPAC Name
{5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-2-carbamoyl-1-hydroxyethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-(4-{5-[4-(pentyloxy)phenyl]-1,2-oxazol-3-yl}benzamido)-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0⁹,¹³]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl}oxidanesulfonic acid
SMILES
CCCCCOC1=CC=C(C=C1)C1=CC(=NO1)C1=CC=C(C=C1)C(=O)N[[email protected]]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[[email protected]](O)[C@@H](O)C1=CC(OS(O)(=O)=O)=C(O)C=C1)[[email protected]](O)CC(N)=O
Pharmacology
IndicationFor use in the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.
Structured Indications
PharmacodynamicsFormerly known as FK463, micafungin is a semisynthetic lipopeptide synthesized from a fermentation product of Coleophoma empetri that works as an antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis. Depending on its concentration, micafungin may be fungicidal against some Candida, but is usually fungistatic against Apergillus. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.
Mechanism of actionMicafungin inhibits the synthesis of beta-1,3-D-glucan, an essential component of fungal cell walls which is not present in mammalian cells. It does this by inhibiting beta-1,3-D-glucan synthase.
TargetKindPharmacological actionActionsOrganismUniProt ID
1,3-beta-glucan synthase component FKS1Proteinyes
inhibitor
Aspergillus niger (strain CBS 513.88 / FGSC A1513)A2QLK4 details
Related Articles
AbsorptionNot absorbed orally
Volume of distribution
  • 0.39 ± 0.11 L/kg [adult patients with esophageal candidiasis]
Protein bindingHighly (>99%) protein bound in vitro, independent of plasma concentrations over the range of 10 to 100 µg/mL. The primary binding protein is albumin; however, micafungin, at therapeutically relevant concentrations, does not competitively displace bilirubin binding to albumin. Micafungin also binds to a lesser extent to a1-acid-glycoprotein.
Metabolism

Micafungin is metabolized to M-1 (catechol form) by arylsulfatase, with further metabolism to M-2 (methoxy form) by catechol-O-methyltransferase. M-5 is formed by hydroxylation at the side chain (w-1 position) of micafungin catalyzed by cytochrome P450 (CYP) isozymes. Even though micafungin is a substrate for and a weak inhibitor of CYP3A in vitro, hydroxylation by CYP3A is not a major pathway for micafungin metabolism in vivo.

Route of eliminationFecal excretion is the major route of elimination (total radioactivity at 28 days was 71% of the administered dose).
Half life14-17 hours
Clearance
  • 0.359 +/- 0.179 mL/min/kg [Adult Patients with IC with 100 mg]
  • 0.321 +/- 0.098 mL/min/kg [HIV- Positive Patients with EC with 50 mg]
  • 0.327 +/- 0.093 mL/min/kg [HIV- Positive Patients with EC with 100 mg]
  • 0.340 +/- 0.092 mL/min/kg [HIV- Positive Patients with EC with 150 mg]
  • 0.214 +/- 0.031 mL/min/kg [hematopoietic stem cell transplant recipients 3 mg/kg]
  • 0.204 +/- 0.036 mL/min/kg [hematopoietic stem cell transplant recipients 4 mg/kg]
  • 0.224 +/- 0.064 mL/min/kg [hematopoietic stem cell transplant recipients 6 mg/kg]
  • 0.223 +/- 0.081 mL/min/kg [hematopoietic stem cell transplant recipients 8 mg/kg]
ToxicityIntravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.
Affected organisms
  • Aspergillis, Candida and other fungi
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AmlodipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Micafungin.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Micafungin is combined with Amrinone.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Azelnidipine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Micafungin is combined with Azimilide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Barnidipine.Approved
BenidipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Benidipine.Approved
BepridilThe risk or severity of adverse effects can be increased when Micafungin is combined with Bepridil.Approved, Withdrawn
BuspironeThe metabolism of Buspirone can be decreased when combined with Micafungin.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Micafungin.Approved, Investigational
CaiThe risk or severity of adverse effects can be increased when Micafungin is combined with Cai.Investigational
CilnidipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Cilnidipine.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Micafungin is combined with Cinnarizine.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Micafungin.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Clevidipine.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Micafungin.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Micafungin.Approved, Investigational, Vet Approved
DarodipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Darodipine.Experimental
DidanosineDidanosine can cause a decrease in the absorption of Micafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Micafungin is combined with Diltiazem.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Micafungin.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Micafungin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Micafungin is combined with Dotarizine.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Efonidipine.Approved
EntacaponeThe metabolism of Micafungin can be decreased when combined with Entacapone.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Micafungin is combined with Eperisone.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Micafungin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Micafungin is combined with Fendiline.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Micafungin is combined with Flunarizine.Approved
FosphenytoinThe serum concentration of Micafungin can be decreased when it is combined with Fosphenytoin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Micafungin is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Micafungin is combined with Gallopamil.Investigational
IsradipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Isradipine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Micafungin is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Lercanidipine.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Micafungin.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Micafungin is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Manidipine.Approved
MibefradilThe risk or severity of adverse effects can be increased when Micafungin is combined with Mibefradil.Withdrawn
NaftopidilThe risk or severity of adverse effects can be increased when Micafungin is combined with Naftopidil.Investigational
NicardipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Micafungin is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Micafungin is combined with Nitrendipine.Approved
PerhexilineThe risk or severity of adverse effects can be increased when Micafungin is combined with Perhexiline.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Micafungin.Approved, Vet Approved
PimozideMicafungin may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Micafungin is combined with Pinaverium.Approved
PregabalinThe risk or severity of adverse effects can be increased when Micafungin is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Micafungin is combined with Prenylamine.Withdrawn
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Micafungin.Approved, Vet Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Micafungin.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Micafungin.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Micafungin.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Micafungin.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Micafungin.Approved
RisedronateThe risk or severity of adverse effects can be increased when Micafungin is combined with Risedronate.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Micafungin.Approved
SucralfateSucralfate can cause a decrease in the absorption of Micafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Micafungin.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Micafungin.Approved, Investigational
Testosterone PropionateThe metabolism of Micafungin can be decreased when combined with Testosterone Propionate.Approved, Vet Approved
TolcaponeThe metabolism of Micafungin can be decreased when combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Micafungin is combined with Tolfenamic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Micafungin is combined with Tranilast.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Micafungin is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Micafungin is combined with Vinpocetine.Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Micafungin is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Micafungin is combined with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Micafungin.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Grover ND: Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol. 2010 Feb;42(1):9-11. doi: 10.4103/0253-7613.62396. [PubMed:20606829 ]
  2. Bormann AM, Morrison VA: Review of the pharmacology and clinical studies of micafungin. Drug Des Devel Ther. 2009 Dec 29;3:295-302. [PubMed:20054447 ]
  3. Vehreschild JJ, Cornely OA: Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice. Future Microbiol. 2006 Aug;1(2):161-70. [PubMed:17661660 ]
  4. Groll AH, Stergiopoulou T, Roilides E, Walsh TJ: Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs. 2005 Apr;14(4):489-509. [PubMed:15882123 ]
  5. Chandrasekar PH, Sobel JD: Micafungin: a new echinocandin. Clin Infect Dis. 2006 Apr 15;42(8):1171-8. Epub 2006 Mar 14. [PubMed:16575738 ]
  6. Wiederhold NP, Lewis JS 2nd: The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155-66. [PubMed:17516879 ]
  7. Ikeda F, Tanaka S, Ohki H, Matsumoto S, Maki K, Katashima M, Barrett D, Aoki Y: Role of micafungin in the antifungal armamentarium. Curr Med Chem. 2007;14(11):1263-75. [PubMed:17504145 ]
  8. Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep 1. [PubMed:19724014 ]
  9. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703. [PubMed:16960253 ]
  10. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20. [PubMed:16990627 ]
External Links
ATC CodesJ02AX05
AHFS Codes
  • 8:14.16
PDB EntriesNot Available
FDA labelDownload (139 KB)
MSDSDownload (84.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8383
Blood Brain Barrier-0.8524
Caco-2 permeable-0.6464
P-glycoprotein substrateSubstrate0.7906
P-glycoprotein inhibitor INon-inhibitor0.6752
P-glycoprotein inhibitor IINon-inhibitor0.9279
Renal organic cation transporterNon-inhibitor0.9428
CYP450 2C9 substrateNon-substrate0.8485
CYP450 2D6 substrateNon-substrate0.7911
CYP450 3A4 substrateSubstrate0.5853
CYP450 1A2 substrateNon-inhibitor0.7414
CYP450 2C9 inhibitorNon-inhibitor0.7017
CYP450 2D6 inhibitorNon-inhibitor0.8251
CYP450 2C19 inhibitorNon-inhibitor0.693
CYP450 3A4 inhibitorInhibitor0.5393
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7703
Ames testNon AMES toxic0.563
CarcinogenicityCarcinogens 0.5763
BiodegradationNot ready biodegradable0.9916
Rat acute toxicity2.5651 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9686
hERG inhibition (predictor II)Inhibitor0.716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous10 mg/mL
Injection, powder, lyophilized, for solutionIntravenous20 mg/mL
Powder, for solutionIntravenous100 mg
Powder, for solutionIntravenous50 mg
Prices
Unit descriptionCostUnit
Mycamine 100 mg vial224.4USD vial
Mycamine 50 mg vial112.2USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2044746 No2001-08-072011-06-17Canada
CA2202058 No2007-11-062015-09-29Canada
US5376634 No1994-12-272011-12-27Us
US6107458 No1999-03-162019-03-16Us
US6265536 No1995-09-292015-09-29Us
US6774104 No2001-01-082021-01-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityFreely soluble as sodium salt (> 200mg/mL)Not Available
logP-1.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.218 mg/mLALOGPS
logP0.67ALOGPS
logP-6.3ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)-2.2ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count22ChemAxon
Hydrogen Donor Count16ChemAxon
Polar Surface Area510.14 Å2ChemAxon
Rotatable Bond Count18ChemAxon
Refractivity303.07 m3·mol-1ChemAxon
Polarizability128.22 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentCyclic peptides
Alternative Parents
Substituents
  • Cyclic alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • Macrolactam
  • Phenylsulfate
  • Benzoic acid or derivatives
  • Benzamide
  • Phenol ether
  • Benzoyl
  • Sulfuric acid monoester
  • Phenol
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • Sulfuric acid ester
  • Sulfate-ester
  • Fatty amide
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Oxazole
  • Organic sulfuric acid or derivatives
  • Isoxazole
  • Azole
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Primary carboxylic acid amide
  • Polyol
  • Lactam
  • Carboxamide group
  • 1,2-diol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid amide
  • Alkanolamine
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Aspergillus niger (strain CBS 513.88 / FGSC A1513)
Pharmacological action
yes
Actions
inhibitor
General Function:
1,3-beta-d-glucan synthase activity
Specific Function:
Catalytic subunit of the 1,3-beta-glucan synthase. Synthesizes 1,3-beta-glucan, a major structural component of the cell wall. Involved in cell wall synthesis, maintenance and cell wall remodeling (By similarity).
Gene Name:
fksA
Uniprot ID:
A2QLK4
Molecular Weight:
216972.8 Da
References
  1. Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep 1. [PubMed:19724014 ]
  2. Quindos G, Eraso E, Javier Carrillo-Munoz A, Canton E, Peman J: [In vitro antifungal activity of micafungin]. Rev Iberoam Micol. 2009 Mar 31;26(1):35-41. doi: 10.1016/S1130-1406(09)70006-3. Epub 2009 May 7. [PubMed:19463275 ]
  3. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703. [PubMed:16960253 ]
  4. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20. [PubMed:16990627 ]
  5. Jarvis B, Figgitt DP, Scott LJ: Micafungin. Drugs. 2004;64(9):969-82; discussion 983-4. [PubMed:15101786 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sulfuric ester hydrolase activity
Specific Function:
Hydrolyzes cerebroside sulfate.
Gene Name:
ARSA
Uniprot ID:
P15289
Molecular Weight:
53587.6 Da
References
  1. Groll AH, Stergiopoulou T, Roilides E, Walsh TJ: Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs. 2005 Apr;14(4):489-509. [PubMed:15882123 ]
  2. Wiederhold NP, Lewis JS 2nd: The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155-66. [PubMed:17516879 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Groll AH, Stergiopoulou T, Roilides E, Walsh TJ: Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs. 2005 Apr;14(4):489-509. [PubMed:15882123 ]
  2. Wiederhold NP, Lewis JS 2nd: The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155-66. [PubMed:17516879 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:38